Similar articles

• Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.

  Kamal SM, Ahmed A, Mahmoud S, Nabegh L, El Gohary I, Obadan I, Hafez T, Ghoraba D, Aziz AA, Metaoei M. Kamal SM, et al. Liver Int. 2011 Mar;31(3):401-11. doi: 10.1111/j.1478-3231.2010.02435.x. Epub 2011 Jan 11. Liver Int. 2011. PMID: 21281434 Clinical Trial.
• Effectiveness of pegylated interferon/ribavirin combination in 'real world' patients with chronic hepatitis C virus infection.

  Borroni G, Andreoletti M, Casiraghi MA, Ceriani R, Guerzoni P, Omazzi B, Terreni N, Salerno F. Borroni G, et al. Aliment Pharmacol Ther. 2008 May;27(9):790-7. doi: 10.1111/j.1365-2036.2008.03657.x. Epub 2008 Feb 21. Aliment Pharmacol Ther. 2008. PMID: 18298638
• Pegylated interferon alpha-2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy.

  Liu CH, Liang CC, Liu CJ, Tsai HB, Hung PH, Hsu SJ, Chen SI, Lin JW, Lai MY, Chen JH, Chen PJ, Chen DS, Kao JH. Liu CH, et al. Gut. 2009 Feb;58(2):314-6. doi: 10.1136/gut.2008.165076. Gut. 2009. PMID: 19136527 No abstract available.
• A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials.

  Zhao S, Liu E, Chen P, Cheng D, Lu S, Yu Q, Wang Y, Wei K, Yang P. Zhao S, et al. Clin Ther. 2010 Aug;32(9):1565-77. doi: 10.1016/j.clinthera.2010.08.009. Clin Ther. 2010. PMID: 20974315 Review.
• Pharmacotherapy of chronic hepatitis C virus infection - the IDEAL trial: '2b or not 2b (= 2a), that is the question'.

  Toyoda H, Kumada T. Toyoda H, et al. Expert Opin Pharmacother. 2009 Dec;10(17):2845-57. doi: 10.1517/14656560903321521. Expert Opin Pharmacother. 2009. PMID: 19891593 Review.